this round of financing will be used for the research and development iteration of the company's vascular interventional surgery robot, the expansion of product indications and the acceleration of clinical promotion.
At the same time, Weiya Medical signed a strategic cooperation agreement with Guichuang Tongqiao. Guichuang Tongqiao will continue to empower the resources in the field of vascular intervention, and accelerate the work of micro-sub-medical vascular interventional surgery robots in product research and development, clinical cooperation, registration and commercialization, so as to realize the coordinated development of their products and businesses and meet the wider clinical needs of vascular interventional surgery.
Weiya Medical Technology Co., Ltd. was established in February 221, which is a high-tech enterprise dedicated to the international cutting-edge vascular interventional surgery robot. The company's main product, minimally invasive vascular interventional surgery robot, is at the international advanced and domestic leading level. In April 221, a new generation of surgical robots developed by Weiya Medical successfully carried out animal experiments in Fuwai Hospital in Beijing, which won unanimous praise from top cardiovascular experts in China.
In the field of vascular interventional surgery robots, Micro-Asia Medical is a rare excellent team with more than ten years of research and development experience in China. A new generation of vascular interventional surgery robot launched by Micro-sub-medical can simultaneously carry out angiography and interventional therapy of coronary artery, nerve and peripheral surgery.
Compared with other products in overseas markets, the robot products of Weiya Medical can complete the operation with robots in the whole process, and the clinical application scenarios are significantly increased.
In terms of core technology, Weiya Medical has a brand-new and original delivery technology, which has achieved breakthrough upgrades in key areas such as delivery accuracy, stability and safety, and can fully meet the needs of doctors in interventional surgery. The products have been recognized by many top experts in China.
In the future, Weiya Medical will continue to deepen product upgrading, continuously improve product application ability and key technological breakthroughs, combine surgical robots with telemedicine, build an integrated platform for vascular interventional telemedicine, and contribute to the construction of vascular interventional telemedicine system.
Dr. Zhao Zhong, chairman of Guichuang Tongqiao, said: Weiya Medical is a leader in the field of vascular interventional surgery robots in China, with profound technical accumulation and rich experience in research and development of medical and industrial integration. The breakthrough technology of micro-sub-medical surgical robot products is expected to form a synergistic effect with the peripheral and nerve intervention products of Guichuang Tongqiao, which will realize the technological innovation of vascular intervention and benefit doctors and patients. We believe that this strategic investment will help the company to build a comprehensive treatment platform for vascular diseases and further enhance the market competitiveness of Guichuang Tongqiao.
ma jinbo, vice president of boyuan capital investment, said: vascular interventional surgery robot has both clinical, commercial and social values, and it is a subdivision product worthy of continuous layout in the field of medical science and technology. We believe that micro-sub-medicine is expected to become a leading enterprise in the field of vascular interventional surgery robots in China because of its deep understanding of clinical application of robots and the iterative ability of breakthrough technology. Boyuan Capital and Guichuang Tongqiao will give full play to their respective advantages in the capital market and industry, work together with Weiya Medical, continue to solve the unmet clinical needs with breakthrough innovative technology, and subvert the future of vascular interventional surgery with scientific and technological innovation.
The founder of Weiya Medical said: For more than 1 years, the founding team of Weiya Medical has firmly focused on solving clinical needs, based on the research and development of underlying technologies, and committed itself to creating subversive products. Over the years, it has achieved remarkable product results. Micro-sub-medical care will not be satisfied with the current achievements, and will continue to exert product iteration and technology research and development, and continue to explore the technological breakthrough of vascular interventional surgery robots in more complicated operations and diversified applications in telemedicine, so as to meet the needs of a wide range of doctors and patients to improve the curative effect of interventional surgery.
Attached
For more project information, please go to.